


For immediate release

The Portuguese Association for CDG (APCDG) and Anaxomics Biotech announce strategic partnership in Congenital Disorders of Glycosylation (CDG).

Lisbon, 21th June 2016 – The Portuguese Association for CDG (APCDG, <http://www.apcdg.com>) today announced her collaboration with Anaxomics Biotech, a company committed to the discovery and development of new and better drugs to improve human health. This strategic partnership occurs under the scope of the CDG & Allies - Professionals and Patient Associations International Network (CDG & Allies-PPAIN).

Congenital Disorders of Glycosylation (CDG) are one of the fastest growing groups among the more than 8000 monogenetic diseases currently known. As for the majority of rare genetic disorders, no effective treatment is known for CDG, and only three CDG types have a therapy.

[Anaxomics Biotech](#) is a leading company that exploits the latest advances in [systems biology](#) to accelerate drug development and biomedical research. “CDG urges multidisciplinary teams and approaches to be deciphered”, mentions Vanessa Ferreira PhD, MBA (sibling to a CDG patient and volunteer coordinator at [CDG & Allies-PPAIN](#)). “After identifying several biotech companies, Anaxomics Biotech was the one meeting all our needs and criteria to move forward into a collaboration aimed at accelerating therapies for CDG”, added Vanessa.



“Anaxomics Biotech brings to CDG cutting-edge systems biology approaches to integrate scientific knowledge and molecular data with a clear spin on novel therapeutic strategies readily applicable to clinical practice”, referred Teresa Sardon PhD (Head of Analytical Services at Anaxomics).

“We’re impressed by Anaxomics genuine solutions and patient-centric approach. Under the scope of CDG & Allies-PPAIN, we will bring benefits for the overall CDG community”, said Vanessa.

More information:

About Anaxomics Biotech: Anaxomics Biotech is committed to the discovery and development of new and better drugs to improve human health. Anaxomics goal is to help the biopharma industry to maximize the value of their discovery and clinical development by leveraging the potential indications of all the compounds in their pipeline, and by identifying and minimizing their potential safety risks. Anaxomics is a client-focused company, with strong stress in quality and innovative approaches to solve current bottlenecks in drug discovery and clinical development. More information [HERE](#).

About CDG & Allies-PPAIN: With the help of a broad network of scientists, physicians, families and patient advocacy groups, we have established a patient-led national and internationally unrivaled infrastructure for research, awareness and education for CDG. The research on Glycosylation disorders is primarily dedicated to Congenital Disorders of Glycosylation (CDG). The advances and innovations achieved for CDG through CDG & Allies - PPAIN will impact on a large number of patients. Namely, the overall human diseases characterized by abnormal protein glycosylation such as cancer, inflammation, Alzheimer's disease and diabetes. Learn more [HERE](#).

What is Systems biology? Read more [HERE](#).

Contact: Rita Francisco, MSc Molecular Genetics (Researcher at Working Group CDG & Heart. Learn more [HERE](#). CDG community social manager). **Email:** publicationscdg@gmail.com